Dexlansoprazole, a new dual-delayed release technology for the treatment of reflux disease, accepted for national approvals within the European Union
Zurich Switzerland (ots) - Takeda Pharmaceuticals International GmbH ("Takeda") announced that the European decentralised procedure (DCP) was positively concluded for dexlansoprazole, a proton pump inhibitor (PPI) with a new dual- delayed release technology for the treatment of reflux disease. The regulatory process ...
mehr